Group 1 - The core point of the article is that Jiukang Bio has received a medical device registration certificate from the Beijing Drug Administration for products including "D-Dimer Calibration Products" [1] - Jiukang Bio's revenue composition for the year 2024 is projected to be 100% from the healthcare sector [1] - As of the report, Jiukang Bio has a market capitalization of 7.8 billion yuan [1] Group 2 - The article also mentions Yang Lingjiang's acquisition of a leading domestic winery, raising questions about the potential relisting of 1919 [1] - There is a sense of urgency expressed regarding the achievement of a significant financial target, indicating pressure on the company [1]

Core Viewpoint - The company, Jiukang Biological, has received medical device registration certificates from the Beijing Medical Products Administration for three products, enhancing its product line in the in vitro diagnostic sector [1] Group 1 - The products that received registration include D-Dimer calibrator, calcitonin assay kit (magnetic microparticle chemiluminescent immunoassay), and mycophenolic acid assay kit (IMPDH II method) [1] - The acquisition of these medical device registration certificates enriches the company's offerings in the biochemical, chemiluminescent, and coagulation subfields of in vitro diagnostics [1]

Core Viewpoint - Company Jiukang Bio (300406.SZ) has received a medical device registration certificate from the Beijing Drug Administration for three products, enhancing its product line in the in vitro diagnostic sector [1] Group 1: Product Registration - The products that received registration include "D-Dimer Calibration Product," "Calcitonin Assay Kit (Magnetic Particle Chemiluminescence Immunoassay)," and "Mycophenolic Acid Assay Kit (IMPDH II Method)" [1] - The acquisition of these medical device registration certificates enriches the company's offerings in the fields of biochemical diagnostics, chemiluminescence, and coagulation [1] Group 2: Impact on Company - The new product registrations are expected to enhance the company's core competitiveness and market expansion capabilities [1] - The developments are anticipated to have a positive impact on the company's future operations [1]

Core Viewpoint - The company, Jiukang Biological, has received medical device registration certificates from the Beijing Drug Administration for three products, enhancing its product line in the in vitro diagnostic sector and positively impacting its future operations [1] Group 1: Product Registration - The products that received registration include "D-Dimer Calibration Product," "Calcitonin Assay Kit (Magnetic Microparticle Chemiluminescent Immunoassay)," and "Mycophenolic Acid Assay Kit (IMPDH II Method)" [1] - The acquisition of these medical device registration certificates enriches the company's offerings in the biochemical, chemiluminescent, and coagulation subfields of in vitro diagnostics [1] Group 2: Competitive Advantage - The new product registrations are expected to enhance the company's core competitiveness and market expansion capabilities [1] - The positive impact on the company's future operations is anticipated as a result of these developments [1]

北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | D-二聚体校准品 | 京 械 注 准 20252401009 | Ⅱ | 自批准之日起有效期 至 2030 年 12 月 18 日 | 与本公司或北京美创新 跃医疗器械有限公司的 试剂盒配套使用，用于 D-二聚体检测系统的校 准。 | | 2 | 降钙素测定试剂盒 （磁微粒化学发光 免疫分析法） | 京 械 注 准 20252401003 | Ⅱ | 自批准之日起有效期 至 2030 年 12 月 18 日 | 本试剂盒用于体外定量 测定人血清或血浆中降 钙素（CT）的含量。 | | 3 | 霉酚酸测定试剂盒 （IMPDHⅡ法） | 京 械 注 准 20252400999 | Ⅱ | 自批准之日起有效期 至 2030 年 12 月 18 日 | 本试剂盒用于体外定量 测定人血清中霉酚酸 （MPA）的含量。 | 上 ...

Core Viewpoint - The announcement from Jiukang Bio indicates that a major shareholder has completed a share buyback plan, which may reflect confidence in the company's future performance and could influence market perception positively [1] Group 1 - Jiukang Bio announced that its major shareholder, Yiyao Investment, has completed a share buyback plan from June 23, 2025, to December 22, 2025 [1] - The total shares acquired through the buyback amounted to 2,926,000 shares, representing 0.499% of the company's total share capital [1] - The total amount spent on the buyback was 39,719,980.00 yuan [1]

每经AI快讯，九强生物12月23日晚间发布公告称，持股5%以上的股东中国医药投资有限公司计划自 2025年6月23日至2025年12月22日，通过集中竞价交易、大宗交易等法律法规允许的方式增持公司股 票，计划增持公司股份金额不少于3000万元（含）人民币，增持所需资金为自有资金。公司于2025年12 月22日收到持股5%以上股东国药投资出具的《中国医药投资有限公司关于北京九强生物技术股份有限 公司股份增持计划实施完毕的函》。截至本公告披露日，本次增持计划已实施完毕，国药投资以集中竞 价交易的方式共增持股份2,926,000股，占公司总股本的0.499%，占剔除公司回购账户股份后总股本的 0.502%，增持金额为39,719,980.00元人民币。 （记者 曾健辉） 每经头条（nbdtoutiao）——地产"优等生"受困20亿元到期债务，首次债务展期仍在博弈，明年还有超 百亿元公开债到期 ...

格隆汇12月23日丨九强生物(300406.SZ)公布，公司于2025年12月22日收到持股5%以上股东国药投资出 具的《中国医药投资有限公司关于北京九强生物技术股份有限公司股份增持计划实施完毕的函》。截至 本公告披露日，本次增持计划已实施完毕，国药投资以集中竞价交易的方式共增持股份2,926,000股，占 公司总股本的0.499%，占剔除公司回购账户股份后总股本的0.502%，增持金额为39,719,980.00元人民 币。 ...

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-120 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于公司持股 5%以上股东增持公司股份计划实施完毕的公告 持股 5%以上的股东中国医药投资有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 公司于 2025 年 12 月 22 日收到持股 5%以上股东国药投资出具的《中国医药 投资有限公司关于北京九强生物技术股份有限公司股份增持计划实施完毕的函》。 截至本公告披露日，本次增持计划已实施完毕，国药投资以集中竞价交易的方式 共增持股份 2,926,000 股，占公司总股本的 0.499%，占剔除公司回购账户股份 后总股本的 0.502%，增持金额为 39,719,980.00 元人民币。本次增持前后股东 持股情况如下： | | | | 本次增持前持有的股份 | 占当时剔除 | | 本次增持后持有的股份 | 占当前剔除 | | - ...

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-119 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 1. 本发明涉及一种自润滑回转装置和配备有该自润滑回转装置的检测仪器， 自润滑回转装置，包括：内圈，其设置有开口朝向径向外侧的容纳槽；外圈，其 安装在所述内圈的外围，并设置有与所述容纳槽相对应的凸台，所述凸台位于所 述容纳槽内；以及多个滑动片，其安装在所述凸台上，并位于所述容纳槽内；其 中，所述外圈和所述内圈能够围绕共同的轴线相对彼此转动，并且所述外圈能够 带动所述多个滑动片一起相对于所述内圈转动。本发明其利用滑动片减小内圈和 外圈之间的转动摩擦力，不再需要依赖润滑油脂，减少了维护工作量，另外，本 发明结构简单，制造成本低，有利于设备的模块化设计。 2. 本发明涉及一种偶联物的制备方法。具体而言，本发明的 6- 磷酸葡萄 糖脱氢酶突变体相较于野生型 6- 磷酸葡萄糖脱氢酶包含选自以下的一个突变： D306C、D375C、G426C。使用本发明的 6- 磷酸葡萄糖脱氢酶突变体所制备的检 测试剂盒，其特异性强、灵敏度高、操作方便 ...